Tumor Suppressor Protein p53
"Tumor Suppressor Protein p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
| Descriptor ID |
D016159
|
| MeSH Number(s) |
D12.776.157.687.650 D12.776.260.820 D12.776.624.776.775 D12.776.660.720.650 D12.776.744.845
|
| Concept/Terms |
Tumor Suppressor Protein p53- Tumor Suppressor Protein p53
- p53 Antigen
- TP53 Protein
- TRP53 Protein
- p53 Tumor Suppressor Protein
- pp53 Phosphoprotein
- Phosphoprotein, pp53
- Cellular Tumor Antigen p53
- Oncoprotein p53
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Protein p53".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Protein p53".
This graph shows the total number of publications written about "Tumor Suppressor Protein p53" by people in this website by year, and whether "Tumor Suppressor Protein p53" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 11 | 6 | 17 |
| 1995 | 25 | 8 | 33 |
| 1996 | 24 | 11 | 35 |
| 1997 | 19 | 13 | 32 |
| 1998 | 33 | 37 | 70 |
| 1999 | 27 | 16 | 43 |
| 2000 | 31 | 21 | 52 |
| 2001 | 30 | 21 | 51 |
| 2002 | 34 | 27 | 61 |
| 2003 | 41 | 36 | 77 |
| 2004 | 30 | 26 | 56 |
| 2005 | 28 | 25 | 53 |
| 2006 | 35 | 28 | 63 |
| 2007 | 39 | 28 | 67 |
| 2008 | 28 | 19 | 47 |
| 2009 | 37 | 28 | 65 |
| 2010 | 40 | 28 | 68 |
| 2011 | 51 | 41 | 92 |
| 2012 | 36 | 33 | 69 |
| 2013 | 39 | 30 | 69 |
| 2014 | 42 | 33 | 75 |
| 2015 | 33 | 32 | 65 |
| 2016 | 39 | 30 | 69 |
| 2017 | 35 | 19 | 54 |
| 2018 | 33 | 20 | 53 |
| 2019 | 30 | 25 | 55 |
| 2020 | 22 | 30 | 52 |
| 2021 | 25 | 14 | 39 |
| 2022 | 12 | 33 | 45 |
| 2023 | 12 | 24 | 36 |
| 2024 | 20 | 16 | 36 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Protein p53" by people in Profiles.
-
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):326-334.
-
Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations. Blood. 2024 Dec 05; 144(23):2402-2416.
-
Using multiplexed functional data to reduce variant classification inequities in underrepresented populations. Genome Med. 2024 Dec 03; 16(1):143.
-
What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 2024 Nov 19; 14(1):202.
-
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion. Blood. 2024 10 17; 144(16):1722-1731.
-
Distinct landscape and clinical implications of therapy-related clonal hematopoiesis. J Clin Invest. 2024 Oct 01; 134(19).
-
Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. Cancer Med. 2024 Oct; 13(19):e70310.
-
Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation. Cell Rep Med. 2024 Sep 17; 5(9):101711.
-
Trajectory of primordial follicle depletion is accelerated in obese mice in response to 7,12-dimethylbenz[a]anthracene exposure?. Biol Reprod. 2024 Aug 15; 111(2):483-495.
-
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024 Oct; 189:138-145.